Doxorubicin-Conjugated Iron Oxide Nanoparticles Synthesized by Laser Pyrolysis: In Vitro Study on Human Breast Cancer Cells.
breast human cells
doxorubicin
drug delivery
in vitro cytotoxicity
iron oxide nanoparticles
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
26 Nov 2020
26 Nov 2020
Historique:
received:
02
11
2020
revised:
22
11
2020
accepted:
24
11
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Even today, breast cancer remains a global public problem, with a high mortality rate among women. Nanoparticle (NP) based systems are developed to enhance drug delivery, reducing the toxic effect of medicine molecules. By using iron oxide nanoparticles for cancer treatment, several advantages were highlighted: the ability to target specific locations derived from their magnetic properties and reduced side effects. The aim of this study was to examine on breast cancer cell line the anticancer potential of γ-Fe
Identifiants
pubmed: 33256060
pii: polym12122799
doi: 10.3390/polym12122799
pmc: PMC7760716
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Education and Research and UEFISCDI
ID : Contract no. 63PCCDI/2018 (PN-III-P1-1.2-PCCDI-2017-072), and Nucleu Programme, ctr. no. 16N /08.02.2019.
Références
Sci Rep. 2015 Nov 02;5:15798
pubmed: 26522181
Sci Rep. 2020 Jul 9;10(1):11292
pubmed: 32647151
Histol Histopathol. 2018 Apr;33(4):365-378
pubmed: 28920632
ChemMedChem. 2020 Jan 7;15(1):96-104
pubmed: 31670889
Small. 2005 May;1(5):482-501
pubmed: 17193474
Sci Rep. 2020 Oct 14;10(1):17174
pubmed: 33057106
Nanotechnol Sci Appl. 2016 Aug 19;9:49-67
pubmed: 27578966
Pharmaceutics. 2018 Oct 18;10(4):
pubmed: 30340364
Nano Lett. 2009 May;9(5):1909-15
pubmed: 19344179
Elife. 2012 Dec 18;1:e00090
pubmed: 23256041
Adv Healthc Mater. 2018 Mar;7(5):
pubmed: 29205944
Curr Cancer Drug Targets. 2015;15(1):35-52
pubmed: 25544649
Nanomedicine (Lond). 2017 Jan;12(1):73-87
pubmed: 27876448
Adv Drug Deliv Rev. 2019 Jan 1;138:302-325
pubmed: 30639256
Updates Surg. 2017 Sep;69(3):313-317
pubmed: 28260181
Eur J Cell Biol. 2013 Aug-Sep;92(8-9):247-56
pubmed: 24064045
Biomaterials. 2008 Oct;29(29):4012-21
pubmed: 18649936
Cancer Cell Int. 2018 Sep 4;18:128
pubmed: 30202239
Biomed Opt Express. 2016 May 25;7(6):2400-6
pubmed: 27375954
Biomed Pharmacother. 2017 Nov;95:1209-1218
pubmed: 28931213
Beilstein J Nanotechnol. 2018 Sep 25;9:2533-2545
pubmed: 30345216
Acta Biomater. 2007 Mar;3(2):233-42
pubmed: 17224313
Mol Pharm. 2011 Oct 3;8(5):1669-76
pubmed: 21838321
J Cancer Res Ther. 2014 Oct-Dec;10(4):853-8
pubmed: 25579518
Oxid Med Cell Longev. 2018 Mar 18;2018:7582730
pubmed: 29743983
Int Rev Psychiatry. 2014 Feb;26(1):4-15
pubmed: 24716497
Angew Chem Int Ed Engl. 2008;47(29):5362-5
pubmed: 18551493
J Nanosci Nanotechnol. 2010 Feb;10(2):1223-34
pubmed: 20352781
Curr Oncol Rep. 2018 Jun 6;20(8):61
pubmed: 29876677
Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79
pubmed: 20691229
J Control Release. 2011 May 30;152(1):76-83
pubmed: 21277920
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
Artif Cells Nanomed Biotechnol. 2017 Feb;45(1):6-17
pubmed: 27050642
Clin Breast Cancer. 2000 Sep;1 Suppl 1:S46-51
pubmed: 11970749
Int J Mol Sci. 2018 Nov 06;19(11):
pubmed: 30404148
PLoS One. 2017 Feb 28;12(2):e0172803
pubmed: 28245258
Oncogene. 2005 Jul 14;24(30):4765-77
pubmed: 15870702
Annu Rev Biomed Eng. 2012;14:1-16
pubmed: 22524388
Expert Opin Drug Deliv. 2017 Jan;14(1):123-136
pubmed: 27401941
Int J Nanomedicine. 2018 Mar 29;13:1963-1983
pubmed: 29636611